Paradigm Biopharmaceuticals Limited (ASX:PAR) is an ASX-listed late-stage drug development company focused on delivering new therapies to address unmet medical needs. Paradigm is currently developing pentosan polysulfate sodium (PPS), an FDA-approved drug that has a long track record of safely treating inflammation over 60 years. Paradigm’s primary focus is to develop PPS (under the name Zilosul®) to treat osteoarthritis (OA), with an addressable population of over 72m in key markets (US, EU5, AU, CAN).